Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
about
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuumEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaThe SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioExtensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyIdentification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsInhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Chronic myeloid leukemia: mechanisms of resistance and treatment.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive.Targeting developmental pathways in children with cancer: what price success?Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathwayOptimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Systems biology analysis of protein-drug interactions.Biological therapy and the immune system in patients with chronic myeloid leukemia.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.[Guidelines for vaccination of immunocompromised individuals].Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug.Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Dasatinib Induced Cardiac Tamponade-A Rare Association.Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.Lck is a key target of imatinib and dasatinib in T-cell activation.Dasatinib-induced immunosuppression and recurrent respiratory tract infections.Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues.Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.On the safety of low-dose dasatinib in comorbid and non-comorbid patients: what is real-life? (Reply).Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors.Synergizing Engineered Immunotherapy with Molecularly Targeted Cancer Treatment
P2860
Q24594356-E39263D0-FD25-4BC9-8984-6DB79DDFE351Q26749324-523AD9BA-4111-4D78-80B0-D01112843C42Q33798573-CBF118CF-CBF4-4937-B07F-FCC7088B939FQ33878636-258610C8-F1A0-44F8-91C7-9178864DE32EQ34202277-C1D508C5-0A21-4D2E-84D8-F6EECFF88BE4Q34451624-DEC2EE49-0FD4-4E0C-8164-6DD562818D8AQ34458274-E28B14A9-7197-4E4B-A2C7-EEC2FAFADCC7Q34722000-26C84D4A-F14B-42AB-95FA-408835A6084BQ35117747-800300C2-BB3A-4980-8818-8AC917DDC72FQ35595795-6CF40C9B-2986-4FAA-B30F-F80B5C1C69DCQ35633858-A6205D02-61C2-441B-9DBA-ABACD35AA60BQ36171949-A6E386DA-74DD-4713-82E7-7B875E8F0ABCQ36905620-11B38243-CC24-4F80-908F-C2F278912760Q37098840-C9DD931E-7B55-4444-9269-B5F4FB26928DQ37541654-25875577-2CBD-4FD3-B7B2-9900C79E7C55Q37763106-C844BF67-B59C-4DFA-B52A-D8F1C7835590Q37866150-E6A0B76E-504E-45CB-A4B2-9863A7208821Q37972867-A72B599D-6843-41F3-992C-4921868A3583Q38015742-08E659E7-E33A-4D31-B983-BF07A6383219Q38221107-DFFA89FF-E7E8-4678-BFF9-58928DC9C6F2Q40180908-FE28291D-8306-4A7E-B1B0-D51AF0A1F0EFQ40238365-9C4F6229-2CB4-42DC-8D89-8548C5BFAEF3Q40600058-3C0671D4-11BF-4616-8D55-0DB76E5DA862Q40643461-12C1732A-3898-4E53-966B-3B2CE10287B2Q41356321-E8885E0A-AA65-4A90-A12D-895A102BF7BCQ42293055-68D28FC6-9E1C-4073-AAAE-0738467B4F59Q42930387-790E4927-3BC6-4B0C-8539-920B291783C6Q43165902-BC25B91B-8356-4BD0-AFFB-C317C882292FQ43849289-ACEDFF1F-A714-4C78-904D-F27CBE2C1D29Q44291160-8094A362-15FD-4B20-B44B-6F126B9B19A1Q46253684-3AFAA4B7-32CF-4930-B234-CB99379F2688Q46970334-48068032-B1CE-4EFA-B1A8-0D6609A30B22Q46974306-BF5724BC-9038-4A0F-8ABB-54705B14DDCAQ49291505-0BCB7A2A-A9DF-484C-83BA-ECB75102246EQ54499425-138128FD-E0FD-4717-91A8-A827B7CCE979Q54513274-42AA71C4-F9B7-4EC6-9B89-CE6AD93E752CQ54534916-689A32A8-BF4E-48B4-9C2C-836C9F17E8C3Q55546375-C04719EC-B456-4FD4-A281-F87E4F5DA6E5Q56970013-232ED5C2-BDC5-4B46-9B35-04693ACADF32
P2860
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@en
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@nl
type
label
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@en
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@nl
prefLabel
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@en
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@nl
P2093
P2860
P50
P1476
Immunosuppression and atypical ...... ith dasatinib at 140 mg daily.
@en
P2093
C Baumgartner
C Sillaber
S Herndlhofer
P2860
P304
P356
10.1111/J.1365-2362.2009.02206.X
P577
2009-09-09T00:00:00Z